Why Is Weave Communications (WEAV) Stock Up 32%? Francisco Partners Buys It for $650 Million

TL;DR

• Weave Communications (WEAV) closed up 31.65% at $7.28 Tuesday after agreeing to be bought by private-equity firm Francisco Partners for $7.40 a share in cash, valuing the healthcare-software company at roughly $650 million.
• The offer is a 34% premium to Monday's $5.53 close. Wednesday the stock is sitting at almost exactly the same level, $0.12 below the deal price, a spread of about 1.6%.
• The deal carries no financing contingency (Francisco Partners signed an equity commitment letter covering the full purchase price) and directors and affiliated funds holding about 14.5% of shares have already agreed to vote yes.
• Expected close is Q4 2026, with an outside date of February 18, 2027, extendable to May 18, 2027. The one genuine wrinkle: Francisco Partners already owns AdvancedMD, a rival healthcare-practice software platform it bought for $1.13 billion in 2024, which makes the antitrust review worth watching rather than a rubber stamp.
• Even at the deal price, Weave is still 69% below its $24 IPO price from November 2021.

The Board

A signed cash deal resets the price to the offer, minus a sliver for time, antitrust review and deal-break risk.

Why Is Weave Communications Stock Up Today?

Francisco Partners agreed to buy the whole company for cash, and the stock re-priced almost the entire way to the offer in a single session. Weave shareholders will get $7.40 per share, a 34% premium to Monday's $5.53 close, in an all-cash transaction the company values at approximately $650 million. The stock gapped from $5.53 to $7.28 on Tuesday, a 31.65% move, and has barely budged since.

There's no quarter to parse here. Weave last reported first-quarter revenue of $65.5 million, up 17.4% year over year, a perfectly ordinary print. A buyer named a price well above where the stock was trading, and the market moved to it. That's the same mechanism behind this year's other cash takeouts, from Mapfre's buyout of Safety Insurance to Teledyne's acquisition of Varex Imaging: a fixed price lands, and the stock stops trading on fundamentals and starts trading on deal-close odds.

What Francisco Partners Is Actually Buying

Weave was founded in 2008 in Lehi, Utah, and runs a communications and payments platform for small and mid-sized healthcare practices: dentists, vets, optometrists, med-spas. CEO Brett White said in the deal announcement that "more than 40,000 locations rely on us today." The pitch to Francisco Partners, per White, is deepening the platform's AI features and its "payments and revenue cycle management capabilities."

The company went public in November 2021 at $24 a share, pricing 5 million shares to raise about $120 million. It has been a rough four and a half years since. Revenue has kept growing, from $204.3 million in 2024 to $239 million in 2025, a real double-digit growth rate for a small-cap SaaS name. The stock did not follow: WEAV traded as low as $4.24 in the last year, and even the $7.40 buyout price sits 69% below where the IPO priced. Francisco Partners is paying about 2.7 times 2025 revenue for a company growing in the high teens. That's an unremarkable multiple for take-private software deals this year, closer to a fair price than a rescue or a steal.

I'd flag one more thing before moving on: the deal price of $7.40 is still below Weave's own 52-week high of $8.11. Whoever bought near that high a year ago isn't being made whole by this offer. The 34% premium is measured against Monday's beaten-down close, a different baseline than the stock's best price this year.

The 1.6% Spread, And What It's Pricing

WEAV closed Tuesday at $7.28 against a $7.40 offer, a gap of $0.12, or about 1.6%. That spread is the market's price for three things.

Time. The deal is targeted to close in Q4 2026, and the merger agreement sets an outside date of February 18, 2027 that can stretch to May 18, 2027 if regulatory review runs long. Annualize a 1.6% return over roughly four to five months and it lands somewhere around 4% a year, in the neighborhood of short-term Treasuries. That comparison is exactly how merger-arb funds size a position like this.

Financing risk, mostly retired. Francisco Partners has an equity commitment letter covering the entire purchase price plus fees, so this isn't a leveraged deal that could fall apart if credit markets seize up. The break fees point the same way: Weave owes Francisco Partners $22.8 million if the board walks for a better offer, while Francisco Partners owes Weave $39 million if it fails to close for financing or regulatory reasons. The buyer is on the hook for more than the seller, which is not how a shaky deal gets structured.

Antitrust review, and this is the part worth actually reading. Weave needs Hart-Scott-Rodino clearance, and I'm not going to wave that off as boilerplate here. Francisco Partners already owns AdvancedMD, a cloud practice-management and patient-engagement platform it bought from Global Payments for $1.13 billion back in 2024. AdvancedMD sells to a broader set of practices and is anchored around electronic health records, while Weave's core business is multi-channel messaging and payments layered on top of whatever system a practice already runs. The overlap is real but narrow, which is probably why the deal wasn't priced with the kind of wide, deal-risk spread you'd see if the market expected a serious antitrust fight. Still, a $0.12 spread assumes this clears without a hitch, and it's the one line item in this deal I'd actually watch between now and closing.

Directors and affiliated funds holding about 14.5% of shares have already signed support agreements committing their votes, which takes the stockholder-approval question mostly off the table. There's no traditional go-shop period, but Weave's board kept a fiduciary out with matching rights, so a topping bid isn't structurally blocked, just unlikely without a rival buyer stepping forward.

The Options Angle

Options on a freshly announced cash takeout go quiet, not active. Once a fixed price is on the table, a stock's future outcomes collapse to basically two: the deal closes near $7.40, or it breaks and the stock falls back toward the pre-deal $5-6 range. There is very little room left for the kind of move that makes buying premium worthwhile, and I couldn't source a live, verifiable WEAV option chain this session on a name this thinly traded to check what's actually being quoted.

A covered call struck above $7.40 would collect a small premium for selling upside the stock has almost no organic reason to reach before the deal closes. That's the same trade the market already runs on every merger-arb name, and it's not a structure I'd bother setting up here.

Trade log

#	Stance	Structure	Strikes and expiry	Cost or credit	Spot at writing	Implied move	Conviction	Breakeven
1	Bullish (merger-arb)	Long common stock, held to deal close	None; targeted close Q4 2026, outside date Feb 18, 2027	$7.28 entry	$7.28	Fixed at $7.40 deal price if the deal closes as agreed	6/10	$7.40 target, +1.6%; deal-break case falls back toward $5-6
2	Pass	Any WEAV options structure	N/A, no chain sourced	N/A	$7.28	N/A	4/10	N/A

The One-Line Read

Weave is up 32% because Francisco Partners is buying it for $7.40 a share in cash. The leftover $0.12 spread prices a narrow antitrust overlap with the buyer's other healthcare-software holding at roughly Treasury-bill returns.